A detailed history of Fmr LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Fmr LLC holds 36,871 shares of SNDX stock, worth $804,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,871
Previous 34,070 8.22%
Holding current value
$804,156
Previous $810,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$18.82 - $23.79 $52,714 - $66,635
2,801 Added 8.22%
36,871 $756,000
Q1 2024

May 13, 2024

SELL
$19.71 - $24.57 $130,598 - $162,800
-6,626 Reduced 16.28%
34,070 $810,000
Q4 2023

Feb 13, 2024

SELL
$11.39 - $21.67 $37,427 - $71,207
-3,286 Reduced 7.47%
40,696 $879,000
Q3 2023

Nov 13, 2023

BUY
$14.52 - $21.77 $32,481 - $48,699
2,237 Added 5.36%
43,982 $638,000
Q2 2023

Aug 11, 2023

BUY
$19.35 - $22.31 $3,947 - $4,551
204 Added 0.49%
41,745 $873,000
Q1 2023

May 11, 2023

BUY
$20.66 - $28.98 $6,549 - $9,186
317 Added 0.77%
41,541 $877,000
Q4 2022

Feb 13, 2023

SELL
$20.64 - $26.24 $2.57 Million - $3.27 Million
-124,649 Reduced 75.15%
41,224 $1.05 Million
Q3 2022

Nov 10, 2022

BUY
$18.51 - $24.79 $744,416 - $996,979
40,217 Added 32.01%
165,873 $3.99 Million
Q2 2022

Aug 12, 2022

SELL
$13.64 - $19.48 $860,506 - $1.23 Million
-63,087 Reduced 33.42%
125,656 $2.42 Million
Q1 2022

May 13, 2022

BUY
$14.84 - $22.15 $20,686 - $30,877
1,394 Added 0.74%
188,743 $3.28 Million
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $2.85 Million - $4.21 Million
187,349 New
187,349 $4.1 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.23B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.